Company intelligence / Profile preview

Omgene Life Sciences

Vadodara, Gujarat, Indiaomgene.com ↗

Ownership: Private
Employees: ~90
Development stage: Other

Overview

Omgene has developed over 40 APIs/intermediates with 20 more in development; it has commercialized several peptide and semi-synthetic APIs since 2022. The company is expanding into biosimilars targeting diabetes and oncology but no published clinical trial results are available yet.

Therapeutic areas: Rare DiseasesNeurologyInfectious DiseasesGastroenterologyEndocrinologyOncologyNephrologyWomen's Health
Modalities: PeptidesSemi-synthetic moleculesSynthetic moleculesBiologic (biopharmaceuticals)Oligonucleotides
Industry: Biotech

Partnerships

Collaboration with RGCB BioNest facility for biosimilar research supportPartnerships with various contract manufacturing organizations for API supply

Beyond the preview

Go deeper on Omgene Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omgene Life Sciences.

Explore the full profile